Should an SGLT‑2 inhibitor (e.g., dapagliflozin, empagliflozin) be started in a male patient with impaired renal function (eGFR 28 mL/min/1.73 m²) and possible heart failure with preserved ejection fraction?

SGLT-2 Inhibitor Use in eGFR 28 with Possible HFpEF

Yes, initiate an SGLT-2 inhibitor (specifically dapagliflozin 10 mg daily) in this 28-year-old male with eGFR 28 mL/min/1.73 m² and possible HFpEF, as current guidelines strongly support SGLT-2 inhibitor use down to eGFR ≥20 mL/min/1.73 m² for both heart failure and kidney protection.

Evidence-Based Recommendation

The 2022 ADA/KDIGO consensus guidelines explicitly recommend SGLT-2 inhibitors for patients with eGFR ≥20 mL/min/1.73 m² 1. The KDIGO 2022 guideline provides a 1A recommendation for treating patients with CKD and eGFR ≥20 mL/min/1.73 m² with an SGLT-2 inhibitor 2. This represents the highest level of evidence and strongest recommendation possible.

Agent Selection at eGFR 28

Choose dapagliflozin 10 mg daily as your first-line agent 1, 3:

• Dapagliflozin: Approved for initiation down to eGFR ≥25 mL/min/1.73 m² and can be continued if eGFR falls below 25 until dialysis 1
• Empagliflozin: FDA labeling states "use not recommended with eGFR <45 mL/min/1.73 m²" for glycemic control, though approved for heart failure down to eGFR ≥20 1
• Canagliflozin: Initiation not recommended at eGFR 15-29; may only continue if already established 1

The EMPEROR trials demonstrated efficacy and safety for empagliflozin in patients with eGFR ≥20 mL/min/1.73 m² and heart failure 1, while DAPA-CKD and DAPA-HF trials showed clear benefits for dapagliflozin at eGFR ≥25 mL/min/1.73 m² 1.

Clinical Context for HFpEF

Even with "possible" HFpEF (not yet definitively confirmed), the indication remains strong:

• SGLT-2 inhibitors reduce heart failure hospitalizations and cardiovascular death in HFpEF regardless of diabetes status 4, 5, 6
• The DELIVER and EMPEROR-Preserved trials established benefits in HFpEF patients 5, 6
• Benefits extend to kidney protection independent of heart failure status 1

The evidence for patients with eGFR 20-29 mL/min/1.73 m² is strongest when concomitant albuminuria or heart failure is present 1, making this patient an ideal candidate.

Pre-Initiation Assessment

Before starting, evaluate 2, 1:

1. Volume status: Assess for hypovolemia; if present on diuretics, consider reducing diuretic dose proactively
2. Confirm eGFR: Verify baseline kidney function
3. Check potassium: Baseline level (SGLT-2 inhibitors actually reduce hyperkalemia risk) 7
4. Diabetes status: If diabetic and on insulin/sulfonylureas, anticipate need to reduce doses to prevent hypoglycemia

Monitoring and Risk Mitigation

Expected eGFR Changes

• Anticipate an initial reversible eGFR decline of 2-5 mL/min/1.73 m² within first 4 weeks 7, 8
• This "dip" is hemodynamic, not nephrotoxic, and does not require discontinuation 1, 2
• After initial dip, expect slower long-term eGFR decline compared to no treatment 9, 8

Key Safety Considerations 1

Volume depletion (low absolute risk at low eGFR):

• Monitor for orthostatic symptoms
• Consider reducing loop/thiazide diuretics if patient is volume-tenuous
• Withhold during acute illness with dehydration

Genital mycotic infections (6% vs 1% placebo; lower risk in males):

• Counsel on hygiene
• Most easily treated; severe cases (Fournier's gangrene) are rare

Ketoacidosis (very rare, especially without diabetes):

• If diabetic on insulin: maintain at least low-dose insulin
• Implement sick-day protocol: hold SGLT-2 inhibitor during acute illness, prolonged fasting, or surgery
• Withhold ≥3 days before major surgery 3

Hypoglycemia: Only relevant if on insulin or sulfonylureas

Follow-Up Schedule

• Week 1-4: Recheck eGFR and potassium to document expected dip
• Ongoing: Standard CKD monitoring; no need for increased frequency due to SGLT-2 inhibitor 7

Continuation Strategy

Once initiated, continue dapagliflozin even if eGFR falls below 25 mL/min/1.73 m² unless dialysis is started or drug is not tolerated 1, 2, 3. The DAPA-CKD and DAPA-HF trial protocols specifically allowed continuation below initiation thresholds, demonstrating ongoing benefit 1, 8.

Common Pitfalls to Avoid

1. Don't withhold due to "low eGFR": The threshold is ≥20, not ≥30 or ≥45 (outdated thresholds)
2. Don't stop for initial eGFR dip: This is expected and protective long-term
3. Don't wait for definitive HFpEF diagnosis: Kidney protection alone justifies use at this eGFR
4. Don't choose empagliflozin at eGFR 28: FDA labeling and dosing tables favor dapagliflozin at this level 1

Mortality and Morbidity Benefits

Recent real-world data in advanced CKD (eGFR 15-29) showed SGLT-2 inhibitors associated with 9:

• 38% relative risk reduction in cardiovascular death or heart failure hospitalization
• Slower eGFR decline trajectory: -1.2 vs -3.5 mL/min/1.73 m²/year
• No excess major adverse kidney events compared to standard care

The DAPA-HF and DELIVER pooled analysis demonstrated continued benefit even when eGFR deteriorated to <25 during treatment, with 47% risk reduction in primary outcomes among those with eGFR decline 8.